Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis

Upadacitinib significantly improved patient-reported outcomes in AxSpA patients with bDMARD-IR after 14 Weeks of treatment. There were notable improvements in disease activity, pain, fatigue, function, HRQoL, and work productivity.

Navarro-Compán, et al. report results from SELECT-AXIS 2, a phase 3, randomised, double-blind, parallel-group, placebo-controlled trial. This study shows that upadacitinib is a suitable oral drug for bDMARD-IR AxSpA patients.